Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations from DECLARE-TIMI 58 Trial

Remo H.M. Furtado, Itamar Raz, Erica L. Goodrich, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Philip Aylward, Anthony J. Dalby, Mikael Dellborg, Doina Dimulescu, José C. Nicolau, Anthonius J.M. Oude Ophuis, Avivit Cahn, Ofri Mosenzon, Ingrid Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Stephen D. Wiviott

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations from DECLARE-TIMI 58 Trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science